You do know IMU has other IP which are considered a lot more valuable with an extremely bigger market potential than Azer-Cel and if you look at them then the MC isn't expensive, on the contrary, it's very undervalue right now. All biotech start-up stock are all or nothing but given the amount of IP and only positive clinical trial updates released for them to date then this is relatively low risk considering the market hasn't value the excellent clinical trial update, Fast Track designation and ODD for VAXINIA released for the last 14 months.
This recent clinical trial update and then Fast Track designation and ODD for Azer-Cel might push the pps to consolidate at 5c but the market interest is the clinical trial updates for VAXINIA and especially OASIS (initial). These announcement will be the catalyst for the real re-rate and CVI converting their $20M CN at 4.75c and $26M warrant at 5c in the next 2-5 months.
IMU Price at posting:
4.3¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)